{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:22:27Z","timestamp":1794666147687,"version":"4.9.1"},"reference-count":42,"publisher":"Informa UK Limited","issue":"26","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,11,2]]},"DOI":"10.1080\/14796694.2025.2569553","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T06:00:16Z","timestamp":1760767216000},"page":"3385-3393","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Beamion BCGC-1: phase Ib\/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers"],"prefix":"10.1080","volume":"21","author":[{"given":"Sara","family":"Hurvitz","sequence":"first","affiliation":[{"name":"The University of Washington","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Simonelli","sequence":"additional","affiliation":[{"name":"IRCCS Humanitas Research Hospital","place":["Milan, Italy"]},{"name":"Humanitas University","place":["Pieve Emanuele, Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Yarza","sequence":"additional","affiliation":[{"name":"START CIOCC","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Berz","sequence":"additional","affiliation":[{"name":"Inc","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehisa","family":"Kitano","sequence":"additional","affiliation":[{"name":"Japanese Foundation for Cancer Research","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Del Conte","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Scientific Institute Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Acosta Eyzaguirre","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital, VHIO","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard Gaston","family":"Doger de Speville Uribe","sequence":"additional","affiliation":[{"name":"START Madrid","place":["Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Maier","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma Gmbh & Co., KG","place":["Biberach an der Riss, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damijan","family":"Erzen","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma Gmbh & Co., KG","place":["Biberach an der Riss, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sila","family":"Aykut Yazgili","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma Gmbh & Co., KG","place":["Ingelheim am Rhein, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[{"name":"European Institute of Oncology, IRCCS","place":["Milan, Italy"]},{"name":"University of Milan","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Deng","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[{"name":"Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wang","sequence":"additional","affiliation":[{"name":"Sir Run Run Shaw Hospital Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izuma","family":"Nakayama","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East","place":["Kashiwa, Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East","place":["Kashiwa, Chiba, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.4090"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2782"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2004.n.011"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852748"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-014-0402-y"},{"key":"e_1_3_9_8_1","unstructured":"National Cancer Institute Surveillance. Epidemiology and end results program. Cancer stat facts: female breast cancer subtypes. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.5301\/tj.5000444"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076065"},{"issue":"17","key":"e_1_3_9_11_1","first-page":"LBA1008","article-title":"Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2\u2013positive (HER2+) advanced\/metastatic breast cancer (a\/mBC): interim results from DESTINY-Breast09","volume":"43","author":"Tolaney SM","year":"2025","unstructured":"Tolaney SM, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2\u2013positive (HER2+) advanced\/metastatic breast cancer (a\/mBC): interim results from DESTINY-Breast09. J Clin Oncol. 2025;43(17_suppl):LBA1008.","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0031"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.245"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01823-8"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02937"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104624"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P1-08-08"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.4435"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503119"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073876"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02132-2"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00924-9"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4437"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6725"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914609"},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.005"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.12.011"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06770-6"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.014"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01478-6"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0302"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0306"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1812"},{"issue":"9","key":"e_1_3_9_36_1","first-page":"GS01","article-title":"Her2climb-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer","volume":"84","author":"Hurvitz S","year":"2024","unstructured":"Hurvitz S, Loi S, O\u2019Shaughnessy J, et al. Her2climb-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer. Cancer Res. 2024;84(9_suppl):GS01\u201310.","journal-title":"Cancer Res"},{"key":"e_1_3_9_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1111"},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00412-y"},{"key":"e_1_3_9_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.1023"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01727"},{"key":"e_1_3_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.508"},{"key":"e_1_3_9_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503704"},{"key":"e_1_3_9_43_1","unstructured":"U.S. Food & Drug Administration. FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations"},{"key":"e_1_3_9_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2569553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:08:20Z","timestamp":1763132900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2569553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":42,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2025,11,2]]}},"alternative-id":["10.1080\/14796694.2025.2569553"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2569553","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}